Benjamin Franklin's father, Josiah Franklin, was a tallow chandler, a soap-maker and a candle-maker. Josiah was born at Ecton, Northamptonshire, England on. A down-to-earth guide to writing fiction. The Art and Craft of Fiction. A Writer's Guide. Michael Kardos, Mississippi State University. Any student can get. Of American Women's. Edited by DALE M. $180.00: Hb: 978-1-107-00137-4: 728 pp. The Cambridge History of English Romantic.

Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes Stephen D. Wiviott, M.D., Eugene Braunwald, M.D., Carolyn H.

McCabe, B.S., Gilles Montalescot, M.D., Ph.D., Witold Ruzyllo, M.D., Shmuel Gottlieb, M.D., Franz-Joseph Neumann, M.D., Diego Ardissino, M.D., Stefano De Servi, M.D., Sabina A. Murphy, M.P.H., Jeffrey Riesmeyer, M.D., Govinda Weerakkody, Ph.D., C. Michael Gibson, M.D., and Elliott M. Antman, M.D., for the TRITON–TIMI 38 Investigators N Engl J Med 2007; 357:2001-2015 DOI: 10.1056/NEJMoa0706482. Methods To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

The key safety end point was major bleeding. Results The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. Clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P.

Figure 1 Cumulative Kaplan–Meier Estimates of the Rates of Key Study End Points during the Follow-up Period. Panel A shows data for the primary efficacy end point (death from cardiovascular causes, nonfatal myocardial infarction [MI], or nonfatal stroke) (top) and for the key safety end point (Thrombolysis in Myocardial Infarction [TIMI] major bleeding not related to coronary-artery bypass grafting) (bottom) during the full follow-up period. The hazard ratio for prasugrel, as compared with clopidogrel, for the primary efficacy end point at 30 days was 0.77 (95% confidence interval [CI], 0.67 to 0.88; P.

Figure 2 Hazard Ratios and Rates of the Primary End Point, According to Selected Subgroups of Study Patients. The primary end point was defined as death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke. The percentages are Kaplan–Meier estimates of the rate of the end point at 15 months. For each subgroup, the size of the square is proportional to the number of patients in the subgroups and represents the point estimate of the treatment effect. The overall treatment effect of prasugrel as compared with clopidogrel is represented by the diamond, and the dashed vertical line represents the corresponding overall point estimate. None of the P values for interactions were significant. Glycoprotein IIb/IIIa–receptor antagonist use was that during the index hospitalization.

The short-term and long-term benefits of dual-antiplatelet therapy with aspirin and clopidogrel have been established for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). Despite these benefits, many patients continue to have recurrent atherothrombotic events while receiving standard dual antiplatelet therapy. In addition, important limitations of clopidogrel remain, such as only a modest antiplatelet effect, with substantial interpatient variability and a delayed onset of action. Small clinical studies have suggested that patients with a reduced pharmacologic response to clopidogrel may be at increased risk for adverse clinical events, including myocardial infarction and coronary-stent thrombosis. Prasugrel — a novel thienopyridine — is a prodrug that, like clopidogrel, requires conversion to an active metabolite before binding to the platelet P2Y 12 receptor to confer antiplatelet activity. At the currently studied doses, prasugrel inhibits adenosine diphosphate–induced platelet aggregation more rapidly, more consistently, and to a greater extent than do standard and higher doses of clopidogrel in healthy volunteers and in patients with coronary artery disease, including those undergoing PCI. Phase 2 testing of prasugrel, as compared with clopidogrel, in patients undergoing elective or urgent PCI showed a trend toward fewer ischemic events, with an acceptable safety profile.

Thus, we designed the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38, a phase 3 trial involving patients with acute coronary syndromes with scheduled PCI, comparing a regimen of prasugrel with the standard-dose regimen of clopidogrel approved by the Food and Drug Administration. Although our trial was designed to compare regimens of prasugrel and clopidogrel, it also tests the hypothesis that the use of an agent producing a higher level of inhibition of adenosine diphosphate–induced platelet aggregation and a less-variable response than standard-dose clopidogrel reduces ischemic events. Methods TRITON–TIMI 38 was designed as a collaboration between the TIMI Study Group, the sponsors — Daiichi Sankyo and Eli Lilly — and a steering committee of investigators (see the Appendix). Quintiles Corporation provided data- and site-management services. All key prespecified and exploratory analyses were performed by the TIMI Study Group, using an independent copy of the complete database. The academic authors wrote all drafts of the manuscript and vouch for the veracity and completeness of its content. The database was locked on September 22, 2007; the analyses reported herein were completed on October 26, 2007.

Study Population We enrolled 13,608 patients with acute coronary syndromes (representative of the entire spectrum of those syndromes) with scheduled PCI. Patients were randomly assigned to the clopidogrel group or the prasugrel group in two strata: 10,074 patients with moderate-to-high-risk unstable angina or non–ST-elevation myocardial infarction and 3534 patients with ST-elevation myocardial infarction. The inclusion criteria for patients with unstable angina or non–ST-elevation myocardial infarction were ischemic symptoms lasting 10 minutes or more and occurring within 72 hours before randomization, a TIMI risk score of 3 or more, and either ST-segment deviation of 1 mm or more or elevated levels of a cardiac biomarker of necrosis. Patients with ST-elevation myocardial infarction could be enrolled within 12 hours after the onset of symptoms if primary PCI was planned or within 14 days after receiving medical treatment for ST-elevation myocardial infarction.

Full exclusion criteria have been published previously. Key exclusion criteria included an increased risk of bleeding, anemia, thrombocytopenia, a history of pathologic intracranial findings, or the use of any thienopyridine within 5 days before enrollment. The protocol was approved by the institutional review boards associated with all participating centers, and written informed consent was provided by all patients. Study Protocol A loading dose of study medication (60 mg of prasugrel or 300 mg of clopidogrel) was administered, in a double-blind manner, anytime between randomization and 1 hour after leaving the cardiac catheterization laboratory. Since the protocol was designed as a trial of patients with acute coronary syndromes who were undergoing PCI, the coronary anatomy had to be known to be suitable for PCI before randomization in all patients with unstable angina or non–ST-elevation myocardial infarction, or in those enrolled after medical treatment for ST-elevation myocardial infarction. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. Randomization was to occur before PCI was performed, and the study drug was to be administered as soon as possible after randomization.

The choice of vessels treated, devices used, and adjunctive medication administered to support PCI was left to the discretion of the treating physician. After PCI, patients received maintenance doses of either prasugrel (10 mg) or clopidogrel (75 mg) daily. Use of aspirin was required, and a daily dose of 75 to 162 mg was recommended. Study visits were conducted at hospital discharge, at 30 days, at 90 days, and at 3-month intervals thereafter, for a total of 6 to 15 months. End Points The primary efficacy end point was a composite of the rate of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke during the follow-up period. Key secondary end points at 30 and 90 days were the primary composite end point and a composite of death from cardiovascular causes, nonfatal myocardial infarction, or urgent target-vessel revascularization. Key secondary end points for the entire follow-up period were stent thrombosis and a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or rehospitalization due to a cardiac ischemic event.

Additional prespecified analyses included an analysis of the rates of the primary end point from randomization to day 3 and a landmark analysis of those data from day 3 to the end of the study. Key safety end points were TIMI major bleeding not related to coronary-artery bypass grafting (CABG), non–CABG-related TIMI life-threatening bleeding, and TIMI major or minor bleeding, as previously defined.

Stent thrombosis was defined as definite or probable stent thrombosis according to the Academic Research Consortium. All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments. Statistical Analysis Efficacy comparisons were performed on the basis of the time to the first event, according to the intention-to-treat principle. Safety analyses were carried out on data from patients who received at least one dose of the study drug. The Gehan–Wilcoxon test was used to compare the treatment groups with regard to the primary efficacy end point; the log-rank test was used in a prespecified sensitivity analysis for the primary end point and in all analyses of key secondary and safety end points. Because of the substantial overlap between the cohort of patients with unstable angina or non–ST-elevation myocardial infarction and the overall population of patients with acute coronary syndromes, and to preserve the statistical power to detect a difference between the two treatment groups, we used a closed testing procedure. The primary efficacy end point was analyzed in the cohort with unstable angina or non–ST-elevation myocardial infarction first, and only if there was a statistically significant difference between the treatment groups was this end point analyzed in the overall cohort.

Rates of the end points are expressed as Kaplan–Meier estimates at 15 months and were compared with the use of hazard ratios and two-sided 95% confidence intervals. An independent data monitoring committee monitored the safety and efficacy of the study drugs. P values of less than 0.05 were considered to indicate statistical significance. We calculated that a total of 875 primary end points would be required for the study to have a 90% power to detect a 20% reduction in the relative risk of the primary end point among patients with unstable angina or non–ST-elevation myocardial infarction receiving prasugrel, as compared with clopidogrel. It was estimated that 9500 patients with unstable angina or non–ST-elevation myocardial infarction would need to be enrolled to achieve this number of end points.

A prespecified assessment conducted when 650 patients had had a primary end point found a slightly lower-than-expected aggregate rate of the end point, which led us to increase the number of patients in the cohort with unstable angina or non–ST-elevation myocardial infarction to approximately 10,100. Results We randomly assigned 13,608 patients (10,074 with unstable angina or non–ST-elevation myocardial infarction and 3534 with ST-elevation myocardial infarction), from 707 sites in 30 countries, to a treatment group between November 2004 and January 2007. The baseline characteristics were similar to those in contemporary studies of patients with acute coronary syndromes who were undergoing PCI and were well matched between the treatment groups ( Table 1 Baseline Characteristics of the Patients. The median duration of therapy was 14.5 months. A total of 14 patients (0.1%) were lost to follow-up.

Nearly all patients (99%) had PCI at the time of randomization, 94% received at least one intracoronary stent, and 47% received at least one drug-eluting stent. The study drug was administered before the first coronary guidewire was placed in 25% of patients, after the first coronary guidewire was placed and during the PCI or within 1 hour after PCI in 74%, and more than 1 hour after PCI in 1%. Efficacy End Points The rate of the primary efficacy end point was significantly reduced in favor of prasugrel among the patients with unstable angina or non–ST-elevation myocardial infarction (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P=0.002); therefore, as prespecified, the analysis was also performed in the overall cohort of patients with acute coronary syndromes. A significant benefit of prasugrel was also observed in the ST-elevation myocardial infarction cohort alone (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02), and there was no significant interaction between treatment group and enrollment stratum (unstable angina or non–ST-elevation myocardial infarction vs. ST-elevation myocardial infarction). In the overall cohort, a total of 781 patients (12.1%) in the clopidogrel group had the primary end point, as compared with 643 patients (9.9%) in the prasugrel group (hazard ratio, 0.81; 95% CI, 0.73 to 0.90; P. Safety End Points Among patients treated with prasugrel, 146 (2.4%) had at least one TIMI major hemorrhage that was not related to CABG, as compared with 111 patients (1.8%) treated with clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03) ( Table 3 Thrombolysis in Myocardial Infarction (TIMI) Bleeding End Points in the Overall Cohort at 15 Months.

This excess of TIMI major bleeding included a higher rate of life-threatening bleeding in the prasugrel group (1.4%, vs. 0.9% in the clopidogrel group; hazard ratio, 1.52; 95% CI, 1.08 to 2.13; P=0.01) at the end of the study, as well as from the time of randomization to day 3 (0.4% vs. 0.3%; hazard ratio, 1.38; 95% CI, 0.79 to 2.41; P=0.26) and from day 3 to the end of the study (1.0% vs. 0.6%; hazard ratio, 1.60; 95% CI, 1.05 to 2.44; P=0.03). Fatal TIMI major bleeding occurred in significantly more patients treated with prasugrel (0.4%) than those treated with clopidogrel (0.1%) (P=0.002) ( ), and more patients in the prasugrel group had nonfatal life-threatening bleeding (1.1%, vs. 0.9% in the clopidogrel group; hazard ratio, 1.25; 95% CI, 0.87 to 1.81; P=0.23). A higher rate of TIMI major bleeding related to instrumentation and a significantly higher rate of spontaneous TIMI major bleeding were seen in the prasugrel group than in the clopidogrel group ( ).

Intracranial hemorrhage was reported in 19 patients (0.3%) receiving prasugrel and 17 patients (0.3%) receiving clopidogrel (P=0.74). The combination of non–CABG-related TIMI major or minor hemorrhage was more frequent among patients receiving prasugrel than among those receiving clopidogrel (hazard ratio, 1.31; 95% CI, 1.11 to 1.56; P=0.002) ( ). Few patients underwent CABG; among them, the rate of TIMI major bleeding was also greater with prasugrel than with clopidogrel ( ). More patients treated with prasugrel (2.5%, vs.

1.4% of patients treated with clopidogrel; P. Discussion The risk of myocardial ischemic events in patients with acute coronary syndromes has been shown to be reduced by means of platelet inhibition with the use of aspirin and, even more effectively as compared with the use of aspirin alone, dual-antiplatelet therapy with aspirin and ticlopidine or clopidogrel, two inhibitors of the P2Y 12 adenosine-diphosphate receptor. Our results show that the treatment of patients with acute coronary syndromes, across the full spectrum of such syndromes, with prasugrel (a 60-mg loading dose, followed by a 10-mg maintenance dose), as compared with clopidogrel at the standard, approved dose, resulted in a significant 2.2% absolute reduction and a 19% relative reduction in the rate of the primary efficacy end point (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The rates of ischemic events were also reduced in the prasugrel group, with a 2.3% absolute reduction and a 24% relative reduction for myocardial infarction, a 1.2% absolute reduction and a 34% relative reduction for urgent target-vessel revascularization, and a 1.3% absolute reduction and a 52% relative reduction for stent thrombosis, a rare but potentially devastating clinical event. Our study was not powered to detect a reduction in the rate of death from cardiovascular causes, and no significant benefit was seen for prasugrel over clopidogrel. However, a 0.3% absolute reduction and a 42% relative reduction were found for recurrent myocardial infarction followed by death from cardiovascular causes.

The reduction in the rate of ischemic events by means of antiplatelet agents, including both oral agents (aspirin and clopidogrel) and intravenous agents (glycoprotein IIb/IIIa–receptor antagonists), has uniformly been accompanied by an increase in bleeding. The Antithrombotic Trialists' Collaboration reported a proportional increase in the odds of major bleeding of 60% with the use of antiplatelet agents (largely aspirin), as compared with placebo. In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, therapy with clopidogrel plus aspirin, as compared with aspirin alone, was associated with a 38% increase in the odds of major bleeding.

The reduction in ischemic events we observed with prasugrel as compared with standard-dose clopidogrel was, as expected, associated with a significant increase in the rate of bleeding. The relative rate of TIMI major hemorrhage was increased by 32% with prasugrel ( ). There was an increase in the rate of life-threatening bleeding with prasugrel, including a significant increase in fatal major hemorrhage. Bleeding episodes, including major or life-threatening hemorrhage, were more frequent in the prasugrel group than in the clopidogrel group, both near the time of PCI and after PCI. Though few patients underwent CABG, major bleeding occurred at a higher rate among those receiving prasugrel than among those receiving clopidogrel. This finding suggests that, with a strategy of more potent platelet inhibition, greater attention to the discontinuation of therapy before surgery may be needed. Although the results of post hoc subgroup analyses should be considered exploratory, we identified three subgroups of interest that had less clinical efficacy and greater absolute levels of bleeding than the overall cohort, resulting in less net clinical benefit or in clinical harm.

These included patients with a history of stroke or transient ischemic attack before enrollment, the elderly (age ≥75 years), and those with a body weight of less than 60 kg, risk factors that have been previously identified as being associated with an increased risk of adverse outcomes from the use of antiplatelet or antithrombotic agents. Patients who had had a cerebrovascular event before enrollment in our trial had numerically worse clinical outcomes, as measured in terms of the primary end point, and more frequent bleeding (including intracranial bleeding) than did those without such a history. In previous studies of patients with stroke, dual-antiplatelet therapy has been associated with an increased risk of adverse outcomes, particularly intracranial bleeding, as compared with single-antiplatelet therapy. We therefore believe that our findings regarding prasugrel among patients with a history of cerebrovascular events add to the concerns about the risk of intensive inhibition of platelet aggregation in this population. Among the elderly and among patients with a body weight of less than 60 kg in whom neither net benefit nor net harm was observed, it would be expected that increased levels of the active metabolite of prasugrel may have led to an increased risk of bleeding, owing to altered disposition of the drug or smaller body size. In contrast, a large majority of patients without any of these risk factors had a significant net clinical benefit with the prasugrel regimen studied, as compared with the clopidogrel regimen (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P. Supported by research grants from Daiichi Sankyo and Eli Lilly.

Wiviott and Braunwald, Ms. Murphy, and Drs. Gibson and Antman report receiving research grants from Eli Lilly, Daiichi Sankyo, and Sanofi-Aventis.

In addition, Dr. Wiviott reports receiving consulting fees or paid advisory board fees from Sanofi-Aventis and lecture fees from Eli Lilly and Daiichi Sankyo; Dr. Braunwald, consulting fees or paid advisory board fees from Daiichi Sankyo and Sanofi-Aventis and lecture fees from Eli Lilly and Sanofi-Aventis; Dr. Montalescot, consulting fees or paid advisory board fees, lecture fees, and research grants from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and Dr. Ruzyllo, lecture fees from Eli Lilly.

Ardissino reports receiving consulting fees or paid advisory board fees from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme, and Sanofi-Aventis; lecture fees from Merck Sharp & Dohme and Sanofi-Aventis; and research grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Sanofi-Aventis, and Schering-Plough; and Dr. De Servi, consulting fees or paid advisory board fees from Eli Lilly, lecture fees from Eli Lilly and Sanofi-Aventis, and research grants from Sanofi-Aventis. Riesmeyer and Weerakkody report being employees of Eli Lilly and holding equity ownership or stock options therein. Gibson reports receiving lecture fees from Daiichi Sankyo, Eli Lilly, and Sanofi-Aventis; and Dr. Antman, consulting fees or paid advisory board fees from Sanofi-Aventis and lecture fees from Eli Lilly and Sanofi-Aventis.

No other potential conflict of interest relevant to this article was reported. This article (10.1056/NEJMoa0706482) was published at www.nejm.org on November 4, 2007. Appendix The members of the Operations and Steering Committees of the TRITON–TIMI 38 were as follows (with principal investigators at participating centers listed separately, in the ): TIMI Study Group, Brigham and Women's Hospital, Boston: E.

Braunwald (study chair), E.M. Antman (principal investigator), S. Bullet Raja Hindi Movie Download 3gp. D. Wiviott (investigator), C.M.

Gibson (investigator), C.H. McCabe (director), S.A. Murphy (lead biostatistician), J. Buros (biostatistician), S.

McHale (project manager); Sponsors: Eli Lilly — J. Riesmeyer, J.A. Weerakkody, W. Moscarelli, J. Croaning; Daiichi Sankyo — J.

Bocanegra, J. Hsu; Data Coordinating Center (Quintiles): K. Boyle; Steering Committee: all members of the TIMI Study Group and sponsor staff listed above; France — G. Montalescot (coprincipal investigator), P.G. Steg; Norway — L. Aaberge; Denmark — H.R.

Anderson; Italy — D. Ardissino, S.

De Servi; Australia — P. Aylward; Chile — R.

Corbalan; South Africa — A. Dalby; Slovak Republic — V. Fridrich; United States — M. Kereiakes, N. Popma; Canada — S. Goodman; Israel — S. Gottlieb; Argentina — E.

Gurfinkel; Austria — K. Huber; Hungary — M. Keltai; Spain — J. Lopez-Sendon; Switzerland — T. Luscher; Germany — F.-J.

Schomig; Brazil — J. Nicolau; Poland — W. Ruzyllo; Sweden — F. Schersten; Portugal — R.

Seabra-Gomes; Iceland — A. Sigurdsson; Finland — M. Syvanne; Belgium — F. Van de Werf; the Netherlands — F.

Verheugt; New Zealand — H. White; Czech Republic — P. Widimsky; United Kingdom — R. Wilcox; Data Monitoring Committee: D.O. Williams (chair); D. DeMets (statistician); C. Sigwart; Clinical Events Committee: B.

Scirica (administrative chair), E. Kathiresan, D.

The original logo of the franchise. Created by Original work (1978) Print publications Novel(s) Comics Films and television Film(s) Games Video game(s) (1983) Halloween is an American that consists of ten,,,, and a. The franchise predominately focuses on the fictional character of who was committed to a sanitarium as a child for the murder of his older sister,. Fifteen years later, he escapes to stalk and kill the people of Haddonfield, while being chased by his former psychiatrist. Michael's killings occur on the holiday of, on which all of the films primarily take place. The original, released in 1978, was written by and, and directed by Carpenter. The film is known to inspire a long line of.

Seven sequels have since followed. Michael Myers is the antagonist in all of the films except, the story of which has no direct connection to any other film in the series.

In 2007, writer-director made a of the 1978 film. A to the 2007 remake was released two years later. An 11th film, directed by, is set to be released in October 2018. The films collectively grossed over 366 million at the box-office worldwide. The film series is ranked fourth at the United States box office—in adjusted 2008 dollars—when compared to other American horror franchises. Contents • • • • • • • • • • • • • • Films [ ] Film Director Writer(s) Producer(s) (1978) John Carpenter and Debra Hill (1981) Debra Hill and John Carpenter (1982) (1988) Screenplay by: Story by: Dhani Lipsius & Larry Rattner & Benjamin Ruffner and Alan B. McElroy Paul Freeman (1989) Michael Jacobs & Dominique Othenin-Girard and Shem Bitterman Ramsey Thomas (1995) Daniel Farrands Paul Freeman (1998) Screenplay by: Robert Zappia and Story by: Robert Zappia (2002) Rick Rosenthal Screenplay by: Larry Brand and Story by: Larry Brand (2007) Malek Akkad, Andy Gould and Rob Zombie (2009) Overview [ ] The original (1978), co-written and directed by, tells the story of as he stalks and kills teenage on Halloween night.

The film begins with six-year-old Michael (Will Sandin) killing his teenage sister () on Halloween 1963 in the fictional town of Haddonfield, Illinois. He is subsequently hospitalized at Smith's Grove Sanitarium. Fifteen years later, Michael ( and ) escapes and returns to his hometown where he stalks Laurie Strode () and her friends as they babysit. The film ends with Michael being shot six times by his psychiatrist, (). (1981) picks up where the events of Halloween left off.

Michael's body is missing from the front lawn, where he fell when Loomis shot him. Michael follows Laurie to the local hospital, killing everyone who gets between him and Laurie. The story reveals that Laurie is actually Michael's sister: she was given up for adoption as an infant. Michael corners Loomis and Laurie in an operating room, where Loomis causes an explosion as Laurie escapes.

Michael, engulfed in flames, stumbles out of the room toward Laurie before finally falling dead. Michael Myers does not appear in (1982). This installment follows the story of Dr.

Challis () as he tries to solve the mysterious murder of a patient in his hospital. He, along with the patient's daughter Ellie (), travels to the small town of Santa Mira, California. The pair discover that Silver Shamrock Novelties, a company run by Conal Cochran (), is attempting to use the mystic powers of the rocks to resurrect the ancient aspects of the festival,, which Cochran connects to witchcraft. Cochran is using his Silver Shamrock Halloween masks to achieve his goal, which will be achieved when all the children wearing his masks watch the Silver Shamrock commercial airing Halloween night.

Challis contacts the television stations and convinces all but one of the station managers to remove the commercial. The film ends with Challis screaming for the final station to turn off the commercial. (1988), as the title suggests, features the return of Michael Myers () to the film series. The film reveals that Michael survived the fire in Halloween II but has been in a coma since that night.

While being transferred back to Smith's Grove, Michael comes out of his coma and overhears that Laurie Strode, who died in a car accident, has a daughter, (). Michael escapes the transport and heads to Haddonfield in search of Jamie. Fellow survivor Dr. Loomis also goes to Haddonfield after learning that Michael has escaped transfer. Eventually, the police track Michael down and shoot him several times before he falls down a mine shaft. Picking up directly where the previous film ends, (1989) has Michael () surviving the gunshots, and the fall down the mine; he stumbles upon a hermit who bandages him up.

One year later, and showing signs of a metaphysical connection to Jamie, Michael tracks Jamie to a local child mental health clinic. Using Jamie as bait, Loomis manages to capture Michael. The film ends with Michael being taken into police custody, only to be broken out of jail by a mysterious stranger, all dressed in black.

(1995) picks up the story approximately six years after the events of The Revenge of Michael Myers. The mysterious stranger who broke Michael out of jail kidnaps Jamie Lloyd () in an effort to obtain her illegitimate child. Jamie escapes with her newborn, with Michael (George P. Wilbur) in pursuit. Michael kills Jamie and continues searching for her baby; the infant is found by Tommy Doyle ()—the young boy who was babysat by Laurie Strode in the first film—who brings it home for safety.

It is revealed that Michael is driven by the Curse of, which forces a person to kill their entire family in order to save all of civilization. The mysterious stranger is revealed to be Dr. Loomis’s colleague, Dr.

Wynn (), who is part of a group of people who protect the chosen individual so that they may complete their task. With the help of Kara Strode (), Laurie’s adoptive cousin, Tommy keeps the infant from Michael, who slaughters Wynn and his followers. Michael is finally subdued by Tommy, who injects him with large quantities of tranquilizers inside the Smith’s Grove Sanitarium. The film ends with Loomis walking back into the sanitarium to find Michael. The events that transpire between the fourth to sixth films are effectively ignored in 1998’s.

This film opens twenty years after the events of the second film. Laurie Strode (Jamie Lee Curtis) has faked her own death so that she could go into hiding from her brother Michael.

Now working as the head mistress of a private school under the name Keri Tate, Laurie continues to live in fear of her brother’s return. Her own son, John (), attends school where she teaches. Laurie’s fear becomes reality when Michael (Chris Durand) shows up at the school and begins killing John’s friends and eventually he and Laurie come face-to-face. Laurie manages to get John and his girlfriend () to safety, but decides to return to the school to face Michael once and for all. Laurie succeeds in stopping Michael, but not satisfied until she knows that he is truly dead, Laurie steals his body and decapitates Michael.

(2002) picks up three years after H20, and reveals that Michael swapped clothes with a paramedic—crushing the paramedic’s so that he could not talk—and that was who Laurie killed. Unable to deal with killing an innocent man, and the fact that Michael was still out there, Laurie is committed to a mental institution. Michael (Brad Loree) shows up at the institution, but Laurie captures him. Her fear of making the same mistake twice gets the better of her, and when she attempts to remove Michael’s mask he surprises and kills her. Michael travels back to his family home in Haddonfield, but finds a group of college students filming an. Michael proceeds to kill everyone, until he is finally electrocuted by the only surviving student, Sara Moyer (), and the show’s creator Freddie Harris (). Was released in 2007.

This film focuses on the events that led Michael Myers () to kill his family. It also identifies Laurie as Michael’s sister early on, which was something not done in the original 1978 film. On Halloween, Michael murders a school bully, his older sister and her boyfriend, as well as his mother’s boyfriend. Committed to Smith’s Grove Sanitarium, Michael closes himself off from everyone.

Seventeen years later, Michael () escapes and heads to Haddonfield to find his younger sister, with his psychiatrist Dr. Loomis () in pursuit. Michael finds his sister living with the Strode family, and going by the name Laurie.

After killing all of her friends and family, Michael kidnaps Laurie and attempts to explain to her that he is her brother through the use of a picture that he has kept of himself and her as an infant. Unable to understand, Laurie fights back; eventually, Laurie uses Loomis's gun to shoot Michael in the head. In 2009, a sequel to the remake, titled, picks up right where the latter leaves off and then jumps ahead one year.

Here, Michael (Mane) is presumed dead, but resurfaces after a vision of his deceased mother () informs him that he must track Laurie () down so that they can 'come home' together. In the film, Michael and Laurie have a mental link, with the two sharing visions of their mother. Development [ ] After viewing John Carpenter's film (1976) at the, independent and sought out Carpenter to direct for them a film about a psychotic killer stalking babysitters. Carpenter and began drafting a story titled The Babysitter Murders, but the title was changed at Yablans' request, suggesting the setting be changed to Halloween night and naming it Halloween instead. Moustapha Akkad fronted the $300,000 for the film's budget, even though he was worried about the tight schedule, low budget, and Carpenter's limited experience as a filmmaker.

He finally decided to finance the film after Carpenter relayed the entire film to Akkad, 'in a suspenseful way, almost frame for frame', and opted not to take any fees for directing the film. The low budget forced wardrobe and props to be crafted from items on hand or that could be purchased inexpensively; this included the trademark mask worn by Michael Myers throughout the film.,, and co-editor created Michael's mask from a Halloween mask, purchased for $1.98.

The limited budget also dictated the filming location and time schedule. Halloween was filmed in 21 days in the spring of 1978 primarily in. An abandoned house owned by a church stood in as the Myers house. Two homes on Orange Grove Avenue in were used for the film's climax. 'We investigated a number of 3-D processes [.] but they were far too expensive for this particular project. Also, most of the projects we do involve a lot of night shooting – evil lurks at night.

It's hard to do that in 3-D.' — Debra Hill (writer/producer) on putting Halloween II into. Following the success of Halloween, Yablans and Akkad began working on Halloween II. There was initial discussion about filming Halloween II in, but the idea never came to fruition.

After Halloween II was released, Carpenter and Hill were approached about creating a third Halloween film, but they were reluctant to pledge commitment. The pair agreed to participate in the new project only if it was not a direct sequel to Halloween II, which meant no Michael Myers. Most of the filming for Halloween III took place on location in the small coastal town of Loleta in.

Familiar Foods, a milk bottling plant in Loleta, served as the Silver Shamrock Novelties factory, but all special effects involving fire, smoke, and explosions were filmed at Post Studios. After Halloween III was released, Michael Myers was brought back into the franchise with 1988's The Return of Michael Myers, where he has stayed for the remainder of the series. Four more sequels would follow, between 1988 and 2002, before the series would take a break for five years. On June 4, 2006, announced that, director of and, would be creating the next installment in the Halloween franchise. Bob Weinstein approached Rob Zombie about making the film, and Zombie, who was a fan of the original and friend of, jumped at the chance to make a Halloween film for Dimension Films. Before Dimension went public with the news, Zombie felt obligated to inform John Carpenter, out of respect, of the plans to remake his film.

Carpenter's request was for Zombie to 'make it his own [film]'. Zombie's film would combine the elements of prequel and remake with the original concept, with considerable original content in the new film. Zombie also wanted to reinvent the character, as he felt Michael, along with,, and, had become too familiar to audiences, and as a result, less scary. Zombie delved deeper into Michael Myers's mythology. Michael's mask was even given its own story to provide an explanation as to why he wears it, instead of having the character simply steal a random mask from a hardware store, as in the original film. Zombie wanted to bring Michael closer to what a really is, and wanted the mask to be a way for Michael to hide. In 2008, a sequel to the 2007 remake was announced, with French filmmakers in negotiations to direct.

Instead, Zombie was resigned to write and direct the sequel, with the film taking place directly after the end of his remake. In an interview, Zombie expressed how the exhaustion of creating the first Halloween made him not want to come back for a sequel, but after a year of cooling down he was more open to the idea. The writer/director explains that with the sequel, he was no longer bound by a sense of needing to retain any 'John Carpenter-ness', as he could now do 'whatever [he] wants to do'. Instead of focusing on Michael, Zombie chose to look more at the psychological consequences on Laurie after the events of the remake. As Zombie explains, after Michael murdered her friends and family, Laurie became a 'wreck', who continually sinks lower as the film moves forward. Music [ ] John Carpenter composed the music to the first three films. For Halloween, Carpenter chose to use a played in a instead of a soundtrack.

Critic calls the score 'relatively simple and unsophisticated', but admits that ' Halloween's music is one of its strongest assets.' Carpenter stated in an interview, 'I can play just about any keyboard, but I can't read or write a note.' In the end credits, Carpenter bills himself as the 'Bowling Green Orchestra' for performing the film's score, but he did receive assistance from composer Dan Wyman, a music professor.

John Carpenter's theme for the original Halloween, which was reproduced for the sequels Problems playing this file? The score for Halloween II is a variation of John Carpenter's compositions from the first film, particularly the main theme's familiar piano melody played. The score was performed on a rather than the piano used for Halloween. One reviewer for the described the revised score as having 'a more Gothic feel'.

The reviewer asserted that it 'doesn’t sound quite as good as the original piece', but 'it still remains a classic piece of music'. Music remained an important element in establishing the atmosphere of Halloween III. Just as in Halloween and Halloween II, there was no symphonic score.

Much of the music was composed to solicit 'false ' from the audience. The soundtrack was composed by John Carpenter and Alan Howarth, who had also worked on the score for Halloween II. The score of Halloween III differed greatly from the familiar main theme of the original and its first sequel.

Carpenter replaced the familiar piano melody with a slower, electronic theme played on a synthesizer with beeping. Howarth explains how he and Carpenter composed the music for the third film: The music style of John Carpenter and myself has further evolved in this film soundtrack by working exclusively with synthesizers to produce our music.

This has led to a certain procedural routine. The film is first transferred to a video tape and synchronized to a 24 track; then while watching the film we compose the music to these visual images. The entire process goes quite rapidly and has 'instant gratification', allowing us to evaluate the score in synch to the picture.

This is quite an invaluable asset. Box office [ ] The Halloween franchise, when compared to the other top-grossing American horror franchises—,,, the series,,,, and —and adjusting for the 2017 inflation is the fourth highest grossing horror franchise in the United States at approximately $667.9 million. This list is topped by Friday the 13th at $825.1 million, followed by the Nightmare on Elm Street series with $703.3 million. The Hannibal Lecter film series closely follows in third with $737.6 million. Following Halloween is the Saw series with $580.9 million, Scream with $586.9 million, Psycho with $554.4 million, The Texas Chainsaw Massacre with $391 million, and the Child's Play film series rounding out the list with $249.6 million.

Release date Budget Box office revenue Reference United States Foreign Worldwide 1. Halloween (1978) October 25, 1978 $325,000 $47,000,000 $23,000,000 $70,000,000 2. Halloween II (1981) October 30, 1981 $2,500,000 $25,533,818 $25,533,818 3. Halloween III: Season of the Witch October 22, 1982 $14,400,000 $14,400,000 4. Halloween 4: The Return of Michael Myers October 21, 1988 $5,000,000 $17,768,757 $17,768,757 5. Halloween 5: The Revenge of Michael Myers October 13, 1989 $5,000,000 $11,642,254 $11,642,254 6.

Halloween: The Curse of Michael Myers September 29, 1995 $15,116,634 $15,116,634 7. Halloween H20: 20 Years Later August 7, 1998 $17,000,000 $55,041,738 $30,000,000 $85,041,738 8.

Halloween: Resurrection July 12, 2002 $13,000,000 $30,354,442 $7,310,413 $37,664,855 9. Halloween (2007) August 31, 2007 $15,000,000 $58,272,029 $21,977,438 $80,249,467 10. Halloween II (2009) August 29, 2009 $15,000,000 $33,392,973 $5,312,275 $38,705,248 Total $72,325,000 (A) $308,522,645 $87,600,126 $396,122,771 List indicator(s) • A light grey cell indicates the information is not available for the film. • (A) indicates an estimated figure based on available numbers. Future [ ] On June 21, 2011, it was announced that a new Halloween film, at the time titled Halloween 3D, would be released on October 26, 2012. At the time of the announcement, there was no director or writer attached to the project. Originally, and were labeled as writers but dropped out due to their occupancy on the reboot.

There was no confirmation if a new script had been written or if any cast or crew members from previous films in the series would be involved. The film was dropped from the release schedule on October 26, 2012, as no work had progressed on the film. In February 2015, it was reported that and would be writing a new Halloween film, along with Malek Akkad and Matt Stein producing. On June 15, 2015, it was further reported that was moving ahead with another Halloween sequel, tentatively titled Halloween Returns with Dunstan directing.

The film would've been a standalone film set to reintroduce audiences to Michael Myers years after his initial rampage. It would pit a new group of Haddonfield youngsters against Myers. On October 22, 2015, producer Malek Akkad expressed his wishes to postpone production for the new Halloween film and insists that the next iteration and the extra time will result in a better film. Malek said of Halloween Returns: 'Although, I have to say, and this is somewhat new news, but unfortunately things happen in Hollywood where you have issues with studios and different variables. We've had to take a step back and now we’re trying to re-figure this beast that is the new Halloween. So there is a bit of a delay, but this new Halloween isn't going to be quite what has been announced and what people are expecting, so we're making some changes there as well.'

In December 2015, it was announced that Dimension Films no longer had the rights to the Halloween franchise. The cancellation of the planned film Halloween Returns was confirmed at the same time. On May 23, 2016, it was reported that and were developing a new Halloween film, which they would co-finance. John Carpenter is set to executive produce the project and act as creative consultant.

Carpenter said, 'Thirty-eight years after the original Halloween, I'm going to help to try to make the 10th sequel the scariest of them all.' On February 9, 2017, Carpenter announced that the new Halloween film would be released on October 19, 2018 and was going to be written by and, and directed by Green. It will be a direct sequel to the original film and will ignore all the sequels.

In September 2017, Jamie Lee Curtis confirmed that she would reprise her role as Laurie Strode. And have been casted as Karen Strode and Michael Myers respectively. The film will be distributed by, their first involvement in the franchise since distributing 1982's Halloween III: Season of the Witch. On October 17, 2017, Carpenter announced that he would be returning to score the upcoming film, saying 'I’ll be consulting with the director to see what he feels. I could create a new score, we could update the old score and amplify it, or we could combine those two things. I’ll have to see the movie to see what it requires.' Documentary [ ] 25 Years of Terror is a released on July 25, 2006, featuring a documentary on the Halloween films, narrated by and featuring interviews from many of the cast members as well as filmmakers of the Halloween films and a lot of footage from the series as well.

It has panel discussions with members from the casts and crews of most of the Halloween films, plus other celebrities and filmmakers such as and as well as film critics. All of the panel discussions took place at a 25-year Anniversary convention in (one of the filming locations of the original ) in October 2003. It also has extended versions of interviews featured in the documentary, and much more. [ ] In 2010, produced a titled Halloween: The Inside Story, which premiered on October 28, 2010.

Literature [ ] Novels [ ] When the original Halloween was released in 1978, followed just a year later. Written by Curtis Richards, the book follows the events of the film, but expands on the festival of and Michael's time at Smith's Grove Sanitarium. Halloween II, Halloween III: Season of the Witch, and Halloween 4 each received novelizations as well.

Jack Martin would write Halloween II, which was released alongside its film counterpart. Martin included an additional victim of Michael's in this novel.

Halloween IV, released in October 1988 and written by Nicholas Grabowsky, also followed the events of the film in which it was adapted from. As of 2017, no further films have been novelized. Over a four-month period, published three written by Kelly O'Rourke; the novels are original stories created by O'Rourke, with no direct continuity with the films. The first, released on October 1, 1997, titled The Scream Factory, follows a group of friends who set up a haunted house attraction in the basement of Haddonfield City Hall, only to be stalked and killed by Michael Myers while they are there. The Old Myers Place is the second novel, released December 1, 1997, and focuses on Mary White, who moves into the Myers house with her family.

Michael returns home and begins stalking and attacking Mary and her friends. O'Rourke's final novel, The Mad House, was released on February 1, 1998. The Mad House features a young girl, Christine Ray, who joins a documentary film crew that travels to haunted locations; they are currently headed to Smith Grove Mental Hospital, where they are confronted by Michael. Comic books [ ] The first Halloween comic was published by 's.

Simply titled Halloween, it was intended to be a, but eventually two sequels spawned: Halloween II: The Blackest Eyes and Halloween III: The Devil's Eyes. All of the stories were written by Phil Nutman, with Daniel Farrands—writer for Halloween: The Curse of Michael Myers—assisting on the first issue; David Brewer and Justiniano worked on the illustrations.

Tommy Doyle is the main protagonist in each of the issues, focusing on his attempts to kill Michael Myers. The first issue includes back story on Michael's childhood, while the third picks up after the events of the film Halloween H20. These comics were based on Daniel Farrand's concept for Halloween: Resurrection; he had been approached by the producers to pitch a follow-up to Halloween H20.

His idea was to have Tommy Doyle incarcerated at Smith's Grove for Michael Myers' crimes, only to escape and reunite with Lindsay Wallace. Together, they study the journals of Dr. Loomis and find out more about Michael's childhood. The movie would have explored Michael's time at Smith's Grove and relationship with Dr. Loomis, before returning to Tommy and Lindsay, who are attacked by the adult Michael Myers. Upon defeating him and removing his mask, they discover Laurie Strode, who has taken over her brother's mantle.

Farrand's logic was that, since Jamie Lee Curtis was contracted to cameo in Halloween: Resurrection, they should make that cameo as significant and surprising as possible. Although the studio did not follow up on his pitch, Farrands was able to tell his story in comic book form. One Good Scare was released in 2003; it was written by Stefan Hutchinson and illustrated by Peter Fielding. The main character in this comic is Lindsey Wallace, the young girl who first saw Michael Myers alongside Tommy Doyle in the original 1978 film. Hutchinson wanted to bring the character back to his roots, and away from the 'lumbering -clone' the film sequels had made him. One Good Scare came about because Hutchinson wanted to produce a comic book to celebrate the series' twenty-fifth anniversary; it was to be sold as a collectible at a Halloween convention in South Pasadena. Due to the positive reception to One Good Scare, Hutchinson hoped to use the comic as a 'demo' for getting a distribution deal, but was unable due to rights issues.

While waiting to acquire the rights to publish more Halloween comics, Stefan Hutchinson worked on the documentary Halloween: 25 Years of Terror with Malek Akkad. Together, they developed ideas for possible Halloween stories that would be 'connected into a larger tale, so the idea was that it would use the serial aspect of comic books to create different storylines than would be possible in the films.' On July 25, 2006, as an insert inside the DVD release of 25 Years of Terror, Hutchinson released Halloween: Autopsis.

Written by Hutchinson, and artwork by Marcus Smith and Nick Dismas, the story is about a photographer assigned to take pictures of Michael Myers. As the photographer, Carter, follows Dr. Loomis he begins to take on Loomis's obsession himself, until finally meeting Michael Myers in person, which results in his death. 'A lot of readers found in the comic books what they had been missing from the films in the later sequels. Our books are very faithful to the source material, and by that we mean the original film itself. In our stories, Michael Myers is very much again 'The Shape' — the undefined bogeyman of 1978, rather than the family killer of the 80s and 90s.'

— Stefan Hutchinson on the fan support of his Halloween comic book series. Rob Zombie's reboot of the film series ensured that any Halloween comics would not be contradicted by upcoming films, allowing Hutchinson creative freedom. Malek Akkad was approached by Devil's Due Publishing with the possibility of producing a line of Halloween comics, and he and Hutchinson worked to make them a reality. Hutchinson was convinced by the strong support of One Good Scare that the comic books would have an audience. In 2008, Stefan Hutchinson released the first issue of his new comic book, Halloween: Nightdance. This is a four issue mini-series, and it does not contain any characters—other than Michael—from the films. The four issues are titled, 'A Shape in the Void', 'The Silent Clown', 'A Rainbow in One Color', and 'When the Stars Came Crashing Down'.

The first issue, 'A Shape in the Void', takes place on October 31, 2000, so that it falls between Halloween H20 and Halloween: Resurrection. Issue one follows Michael as he stalks Lisa, an eighteen-year-old girl with insecurities and 'a chronic fear of darkness'. Hutchinson explains that Nightdance was an attempt to escape the dense continuity of the film series and recreate the tone of the 1978 film. Michael becomes inexplicably fixated on Lisa, just as he did with Laurie in the original Halloween, before the sequels established that a sibling bond was actually his motivation for stalking her. The aim was to once again establish Michael Myers as a 'credible and dangerous force'. August 2008 saw the release of Devil's Due's Halloween: 30 Years of Terror to celebrate the thirtieth anniversary of the Halloween franchise.

This comic book one-shot is a collection of short stories inspired by John Carpenter's original. 'Trick or Treat' features the MacKenzies, from the first film who Tommy and Lindsey run to for help. Shows a murder from the of both Michael and his victim, 'Visiting Hours' sees Laurie Strode reflecting on how her life could have been had her brother never found her in 1978, while 'Tommy and the Boogeyman' reveals that Tommy Doyle grew up to write comic books featuring Michael Myers.

In the final story, 'Repetition Compulsion', Dr. Loomis tries to predict where Michael will strike next on Halloween, 1989. Writer Hutchinson explains that H30 came about because, unlike previous decades, there was no Halloween film coming out in 2008 to acknowledge the occasion. Devil's Due released three-issue mini-series Halloween: The First Death of Laurie Strode in late 2008. Written by Hutchinson with artwork from Jeff Zornow, the story bridges the gap between Halloween II and Halloween H20 by focusing on Laurie Strode in the aftermath of the 1978 murders.

Hutchinson explains that Laurie is 'trying to get better and trying to repair, but where do you even start after going through such horror? How do you even try to resume normality when you don't know what that is anymore?' Although Michael appears in the series, it is not clear whether he is real or if the traumatised Laurie is seeing things. Hutchinson is not a fan of the revelation that Laurie and Michael are siblings and took steps to address that problem in the story. He wanted to avoid the 'bloodline plot of the middle sequels', which he felt demystified the character of the Shape, and approach the story so that 'it becomes almost incidental that she's his sister'. Hutchinson believed that Laurie Strode's evolution into Keri Tate was fertile ground for a storyline; he says, 'it's not the faking of the death that's interesting at all, but it’s the fall that leads to that happening.

The faked death is just simple mechanics and can be covered in a sentence, but the state of mind and events leading to that are full of rich character and dramatic potential.' Online stories [ ] All of Stefan Hutchinson's Halloween comic books take place in the Halloween H20 timeline, which retconned Halloween 4– 6 from continuity. Hutchinson comments that, while the retcon was unpopular with 'a lot of fans' for ignoring previous movies, he preferred the 'simplicity of this storyline, over the needlessly convoluted mythology that the last two films had created'. However, he admits that one of the downsides of the H20 timeline is that fans do not know exactly what happened to Dr. Sam Loomis after Halloween II. To remedy this, Hutchinson pitched Halloween: Sam as a way of paying tribute to the character. Written by Hutchinson and featuring illustrations from Autopsis 's Marcus Smith, Sam is a prose short story available exclusively for download at the website HalloweenComics.com.

It explores the life of Dr. Loomis, including his backstory and relationship with Elizabeth Worthington, a journalist he met during. In 1995, Michael Myers visits the ailing Dr. Loomis in hospital, and murders Elizabeth in front of him. Loomis attempts to stop him, but dies of a coronary failure.

Merchandise [ ] In 1983,, who had also released a version of The Texas Chainsaw Massacre, released a Halloween game for the. In the game, the player was a babysitter who had to protect her children from Michael Myers, who had managed to get inside the house. Although the game was called Halloween, and featured the film's theatrical poster as its cover art as well as the movie's main music theme, the game itself never refers to any characters, including the killer, by their names in the film. The Halloween franchise has also seen profitability through various merchandise like toys, dolls, statues, model kits, bobbleheads, snow globes, movie posters, masks, T-shirts, hats, and more.

Michael Myers has made appearances in the form of dolls and toys from, and. Loomis has been immortalized in plastic alongside Michael Myers in a two-figure set produced by NECA.

The Michael Myers mask has been reproduced over the years by, the mask company responsible for the creation of the masks from several of the Halloween films (the Silver Shamrock novelty factory seen in Halloween III was actually shot on location in one of Don Post's factories). While Don Post reproductions of the Michael Myers mask are still commonly found in costume stores every Halloween, the license to produce Michael Myers masks has since been given to Cinema Secrets, the company commissioned with the creation of the Michael Myers mask for Halloween: Resurrection.

As of 2012, Universal Pictures has granted license to Trick or Treat Studios to produce two versions of the Michael Myers mask from Halloween II, one 'clean' version and one with the famous 'blood tears'. Many versions of the original Halloween as well as several of its sequels have been released on and by, Universal Pictures and Dimension Films. In December 2007, there were reports that the Producer's Cut of Halloween: The Curse of Michael Myers might get a DVD release in the future. Following the first Blu-ray release of the original Halloween, all other films in the series were subsequently released to Blu-ray, as well. Home video distributors Anchor Bay Entertainment and released Halloween: The Complete Collection to Blu-ray on September 23, 2014.

This box set brings together all ten Halloween films released to date. Two versions of The Complete Collection were released: a standard 10-disc set featuring the first eight original films of the series and Rob Zombie's 2007 and 2009 remakes, and a 'Limited Edition' 15-disc set, containing the ten films on ten discs, and five extra discs featuring the television versions of Halloween and Halloween II, the never-before released Halloween 6: The Producer's Cut, a bonus disc to Rob Zombie's Halloween, and a bonus disc containing all-new special features from all ten films. The box set won the 2015 Saturn Award for Best DVD/BD Collection Release. Michael Myers and Laurie Strode both appeared as downloadable characters in the game. References [ ]. • (Writer/Director) and Debra Hill (Writer) (1978). United States:.

• Rosenthal, Rick (Director),, and Debra Hill (Writers) (1981). United States:. • Wallace, Tommy Lee (Writer/Director) (1982). United States:. • Little, Dwight (Director) and Allan McElroy (Writer) (1988).

United States: Galaxy International Releasing. • Othenin-Girard, Dominique (Director), Michael Jacobs, Dominique Othenin-Girard, and Shem Bitterman (Writers) (1989). United States: Galaxy International Releasing. • Chappelle, Joe (Director) and Daniel Farrands (Writer) (1995). United States:. • Miner, Steve (Director), Robert Zapia, and Matt Greenberg (Writers) (1998). United States:.

• Rosenthal, Rick (Director), Larry Brand, and Sean Hood (Writers) (2002). United States:. Engineering Materials Book By Rangwala Pdf.

• Zombie, Rob (Writer/Director) (2007). United States:. • Rob Zombie (writer/director) (2009).

Dimension Films. Halloween Movies. Archived from on 2012-05-26. Retrieved 2008-05-22.

Halloween Movies. Halloween Movies.

Archived from on 2012-05-26. Retrieved 2008-05-22.

Seeing Stars. Retrieved 2008-04-05. Halloween Movies. Archived from on 2012-06-29.

Retrieved 2008-05-22. • Carlomagno, Ellen (October 1982). 'Halloween III: Season of the Witch: An On-The-Set Report On The Ambitious Sequel to Carpenter's Classic!' Halloween Movies. Archived from on 2012-09-06. Retrieved 2008-04-05. Halloween Movies.

Archived from on 2013-01-03. Retrieved 2007-04-09. Bloody Disgusting. Archived from on 2007-08-26.

Retrieved 2008-05-22. The Gauntlet.

Retrieved 2008-05-22. Halloween Movies. Archived from on 2013-01-03.

Retrieved 2007-04-09. Retrieved 2008-05-22. Retrieved 2008-05-22.

• Kevin Powers (2008-11-03).. Dead Central.

First Showing. Retrieved 2008-11-04. • Michael Fleming (2008-12-15)...

Retrieved 2008-12-16. • Scott Collura.. Retrieved 2009-03-22. • Scott Collura..

Retrieved 2009-03-22. • James Berardinelli.. Retrieved 2008-05-22. Archived from on June 5, 2008. Retrieved 2008-05-22. Archived from on 2012-06-29.

Retrieved 2008-05-22. Retrieved 2008-05-22. Retrieved 2008-06-30. • Baird, Robert (Spring 2000). 'The Startle Effect: Implications for Spectator Cognition and Media Theory'. Film Quarterly. 53 (3): 12–24..

Archived from on 2006-09-26. Retrieved 2008-05-22. Archived from on 2008-05-09. Retrieved 2008-05-22. Retrieved 2008-05-22.

Retrieved 2008-05-22. Retrieved 2008-05-22. Retrieved 2008-05-22.

Box Office Mojo. Retrieved 2008-09-05.

Box Office Mojo. Retrieved 2008-01-17. Box Office Mojo.

Retrieved 2008-01-17. Box Office Mojo. Retrieved 2008-01-17. Box Office Mojo.

Retrieved 2008-01-17. Retrieved 2008-04-01. Trancas International Films. Archived from on 2012-05-26. Retrieved 2008-12-06. Retrieved 2008-04-01.

Retrieved 2008-04-01. Retrieved 2008-04-01. Retrieved 2008-04-01. Retrieved 2008-04-01. Retrieved 2008-04-01.

Retrieved 2008-04-01. Retrieved 2008-06-18. Retrieved 2007-09-04. Box Office Mojo.

Retrieved 2009-11-25. • Williams, Owen (June 21, 2011).. Empire Online.

Retrieved 2011-06-21. • Turek, Ryan (March 7, 2012).. Shock Till You Drop. Retrieved April 18, 2012.

• Mr Disgusting (June 15, 2015).. Bloody Disgusting.

• Mr Disgusting (June 15, 2015).. Bloody Disgusting. • Hamman, Cody (2015-10-22). JoBlo Movie Network. Retrieved 2015-12-14. • Mitchell, Aric (December 6, 2015).. Retrieved January 7, 2016.

• Hayes, Britt (December 28, 2015).. Retrieved January 7, 2016. • Crow, David (December 28, 2015)..

Den of Geek!. Retrieved January 7, 2016. • Collis, Clark (May 24, 2016).. Retrieved 2015-05-24. • Sacks, Ethan (2016-05-24)... Retrieved 2016-09-28. • Hipes, Patrick (2017-02-09)..

Retrieved 2017-02-09. • Daw, Robbie (2017-10-09)... Retrieved 2017-10-09. • Bierly, Mandi (2017-11-13)... Retrieved 2017-11-14. McBride is keeping mum on plot details, however, other than to confirm what’s already out there. “We’re kind of ignoring all the films past the first one,” he says.

“It picks up after the first one, but it’s sort of an alternate reality. It’s as if the first Halloween ended in a slightly different way.” • (September 15, 2017). Retrieved September 15, 2017 – via.

• N'Duka, Amanda (October 2, 2017)... Retrieved October 11, 2017. • Verhoeven, Beatrice (December 20, 2017).. Retrieved December 20, 2017. Retrieved 2017-10-17.

• Richards, Curtis (October 1979).... • (1981-11-01).. Zebra Publishing.. • Grabowsky, Nicholas (October 1988).. Critics Choice Paperbacks/Lorevan Publishing..

Halloween Movies. Archived from on 2013-01-25. Retrieved 2008-05-22. • O'Rourke, Kelly (1997-10-01)....

• O'Rourke, Kelly (1997-12-01).... • O'Rourke, Kelly (1998-02-01).... Movie Maniacs Comic Books. Retrieved 2008-05-22. Icons of Fright. Retrieved 2008-06-01.

Arrow in the Head. Retrieved 2008-05-22. Retrieved 2008-11-11. Bloody Disgusting. Archived from on 2008-02-26. Retrieved 2008-05-22. Horror Comic Book News.

Retrieved 2008-05-22. Halloween Comics. Retrieved 2008-04-06. Archived from on February 11, 2009. Retrieved 2008-02-04. • Stephen Hutchinson (w), Daniel Zezelj, Jim Daly, Brett Weldele, Jeffrey Zornow, Lee Ferguson, Tim Seeley (p), Nick Bell, Rob Buffalo, Jeffrey Zornow, Elizabeth John (i).

Halloween: 30 Years of Terror (August, 2007), Devil's Due Publishing • Steve Ekstrom (2008-05-06).. Retrieved 2008-06-07. • Steve Ekstrom (2008-08-18).. Retrieved 2008-11-11. Archived from (PDF) on 2008-10-26. Retrieved 2008-11-11.

Retrieved 2008-11-10. Retrieved 2008-06-30. Retrieved 2008-06-30. Halloween Online. Retrieved 2008-06-30. • Slobodzian, Joseph A.

'Unmasking Copyright Companies Face Off Over Film Prop'. The Philadelphia Inquirer. Retrieved 2012-10-17. Archived from on December 14, 2007. Retrieved 2008-04-01. • Morris, Clint (2007-12-12).. Archived from on December 14, 2007.

Retrieved 2008-04-01. Retrieved 28 October 2013. Retrieved 20 July 2014. Retrieved 20 July 2014. Retrieved 2015-11-13.

• Paget, Mat, October 24, 2016, 'Halloween's Michael Meyers Headed to Horror Game Dead by Daylight' ().. Accessed 25th October 2016. External links [ ].